# Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer

> **NCT01301911** · PHASE1 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cipatinib

## Key facts

- **NCT ID:** NCT01301911
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01301911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01301911, "Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01301911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*